PT Ultrajaya Milk Industry & Trading Company Tbk (IDX:ULTJ)

Verve Therapeutics Income Statement

Financials in millions IDR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	8,511,063	8,874,202	8,302,741	7,656,252	6,616,642	5,967,362
Revenue Growth (YoY)	-1.13%	6.88%	8.44%	15.71%	10.88%	-4.11%
Cost of Revenue	5,601,458	5,853,709	5,612,302	5,209,372	4,273,002	3,752,723
Gross Profit	2,909,605	3,020,493	2,690,439	2,446,880	2,343,640	2,214,639
Selling, General & Admin	1,653,635	1,621,486	1,234,366	1,185,036	958,219	1,004,343
Other Operating Expenses	-42,139	-39,598	-40,183	31,757	-238,951	-112,169
Operating Expenses	1,611,496	1,581,888	1,194,183	1,216,793	719,268	892,174
Operating Income	1,298,109	1,438,605	1,496,256	1,230,087	1,624,372	1,322,465
Interest Expense	-131	-127	-46,848	-119,389	-232,065	-27,783
Interest & Investment Income	33,737	37,424	69,861	127,283	155,884	80,239
Earnings From Equity Investments	18,483	21,341	11,057	-20,161	-6,635	10,647
Currency Exchange Gain (Loss)	-15,006	36,743	-6,878	98,951	17,777	60,744
Other Non Operating Income (Expenses)	905	-	-	-1,589	-3,210	-5,847
EBT Excluding Unusual Items	1,336,097	1,533,986	1,523,448	1,315,182	1,556,123	1,440,465
Gain (Loss) on Sale of Assets	-10,908	-15,761	-20,223	-26,184	-14,191	-18,948
Asset Writedown	-11,262	-11,262	4,060	-	-	-
Pretax Income	1,313,927	1,506,963	1,507,285	1,288,998	1,541,932	1,421,517
Income Tax Expense	306,602	353,047	321,124	323,512	265,139	311,851
Earnings From Continuing Operations	1,007,325	1,153,916	1,186,161	965,486	1,276,793	1,109,666
Minority Interest in Earnings	-22,021	-17,292	-16,949	-4,700	-5,155	-9,970
Net Income	985,304	1,136,624	1,169,212	960,786	1,271,638	1,099,696
Net Income to Common	985,304	1,136,624	1,169,212	960,786	1,271,638	1,099,696
Net Income Growth	-24.99%	-2.79%	21.69%	-24.45%	15.63%	6.53%
Shares Outstanding (Basic)	10,398	10,398	10,398	10,398	10,398	11,049
Shares Outstanding (Diluted)	10,398	10,398	10,398	10,398	10,398	11,049
Shares Change (YoY)	-	-	-	-	-5.89%	-4.37%
EPS (Basic)	94.76	109.31	112.44	92.40	122.29	99.53
EPS (Diluted)	94.76	109.31	112.44	92.40	122.29	99.53
EPS Growth	-24.99%	-2.79%	21.69%	-24.45%	22.87%	11.40%
Free Cash Flow	66,408	682,597	1,010,584	-114,520	1,162,362	815,228
Free Cash Flow Per Share	6.39	65.65	97.19	-11.01	111.78	73.78
Dividend Per Share	45.000	45.000	40.000	30.000	25.000	85.000
Dividend Growth	12.50%	12.50%	33.33%	20.00%	-70.59%	608.33%
Gross Margin	34.19%	34.04%	32.40%	31.96%	35.42%	37.11%
Operating Margin	15.25%	16.21%	18.02%	16.07%	24.55%	22.16%
Profit Margin	11.58%	12.81%	14.08%	12.55%	19.22%	18.43%
Free Cash Flow Margin	0.78%	7.69%	12.17%	-1.50%	17.57%	13.66%
EBITDA	1,441,139	1,573,304	1,643,335	1,385,252	1,785,629	1,474,629
EBITDA Margin	16.93%	17.73%	19.79%	18.09%	26.99%	24.71%
D&A For EBITDA	143,030	134,699	147,079	155,165	161,257	152,164
EBIT	1,298,109	1,438,605	1,496,256	1,230,087	1,624,372	1,322,465
EBIT Margin	15.25%	16.21%	18.02%	16.07%	24.55%	22.16%
Effective Tax Rate	23.34%	23.43%	21.30%	25.10%	17.20%	21.94%
Advertising Expenses	-	812,102	468,734	464,091	305,908	335,229

Updated Feb 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.